Conclusion
Through this observation, we come to two conclusions. Firstly, infection
with SARS-CoV-2 could be a differential diagnosis of a PRES related to
anticalcineurins. Nevertheless, it is essential to establish the correct
diagnosis because management depends on it. Secondly, CSA would be a
protective factor against infection by SARS-CoV-2 and its cessation
would not be justified during infection by this virus.